Targeting the "Hunger Hormone": Precision Reagents for Metabolic Disease and Cachexia Research
GHRL (Ghrelin/Obestatin Prepropeptide) encodes the orexigenic hormone ghrelin, a critical regulator of energy homeostasis, growth hormone release, and glucose metabolism. Key documented mutations include rs696217 and rs4684677. As the pharmaceutical industry pivots toward metabolic syndrome, obesity, and cachexia therapeutics, robust assays distinguishing between acyl-ghrelin (active) and des-acyl ghrelin are essential. TarMart provides sequence-verified GHRL antigens, neutralizing antibody benchmarks, GHSR-expressing cell systems, and cross-species reagents to accelerate your anti-ghrelin antibody or ghrelin mimetic development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GHRL drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GHRL Recombinant Protein (Full-length Prepropeptide 1-117aa & Mature Ghrelin 1-28aa) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed. Des-acyl and acyl-mimetic variants available. |
View GHRL Products |
| Gene Delivery | GHRL Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction and secreted expression studies. |
View GHRL Products |
| Receptor System | GHSR (Ghrelin Receptor) Lentivirus & Stable Cell Line Essential for functional ghrelin signaling assays (cAMP flux, calcium mobilization). |
View GHSR Products |
| Benchmark Ab | Anti-GHRL Neutralizing Antibody (Research Grade / Reference Clone) Recombinant positive control for neutralization and detection assays (ELISA/IHC). |
View GHRL Products |
| Validator | GHRL siRNA Set (3 target-specific siRNAs) For knockdown verification and specificity controls. |
View GHRL Products |
| Related Target A | GHSR (Growth Hormone Secretagogue Receptor) Primary receptor for ghrelin; essential for binding and functional assays. |
View GHSR Products |
| Related Target B | GLP1R Synergistic metabolic targeting for obesity/cachexia balance; combination therapy partner. |
View GLP1R Products |
| Related Target C | MBOAT4 (GOAT) Acyltransferase required for ghrelin octanoylation and activation; target for inhibitor development. |
View MBOAT4 Products |
| Related Target D | LEP (Leptin) Counter-regulatory adipokine for metabolic pathway synergy and appetite studies. |
View LEP Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Acylation State Discrimination (Active vs. Inactive) | Des-acyl GHRL recombinant protein (>95% purity) for negative controls; Synthetic acyl-GHRL calibration standards; N-terminal defined acyl-mimetic variants. |
| GHSR-Mediated Functional Validation (GPCR signaling) | GHSR Lentivirus Premade Particles for stable Ca²⁺/cAMP cell lines; preserves native GPCR conformation. |
| Cross-Species Preclinical Evaluation | Human / Mouse / Cyno GHRL ortholog proteins available (>95% purity, theoretical MW verified by mass spec). |
| Obestatin Cross-Reactivity Screening | Obestatin peptide (GHRL 76-98) verified by mass spec for epitope specificity testing. |
| Peptide Stability & Aggregation | High-purity monomeric formulation (sequence verified) with low endotoxin (<1 EU/µg) to minimize assay interference. |
| Lack of Reference Standards | High-purity GHRL prepropeptide provided as ELISA/SPR calibrator. |
| Functional Neutralization Validation | GHSR-Lentivirus stable cell line for cAMP accumulation and calcium flux assays. |
| Assay Specificity & False-Positive Control | Validated GHRL siRNA + isotype controls included for knockdown confirmation. |
Live GHRL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GHRL-targeted therapeutics is intensifying, with major players shifting focus from broad growth hormone secretagogues to tissue-selective GHSR agonists, metabolically stable ghrelin mimetics, and neutralizing monoclonal antibodies. First-generation small-molecule GHSR agonists such as anamorelin (Helsinn/Ono) have established the cachexia market (approved in Japan), while macimorelin is used for adult GH deficiency diagnosis. The next wave includes:
- Neutralizing Antibodies: Novo Nordisk, Lilly and other biotechs are developing anti-ghrelin mAbs for obesity and Prader-Willi syndrome. Early vaccine approaches (e.g., CYT009-GhrQb) have been discontinued due to insufficient immunogenicity.
- Combination Therapies: As GLP-1 agonists dominate obesity, GHRL antagonists/neutralizers are repositioned to mitigate treatment-induced weight loss or muscle wasting, and as combination partners for cachexia.
- GOAT Inhibitors: Targeting ghrelin O-acyltransferase (MBOAT4) to block ghrelin activation is an emerging strategy for metabolic syndrome.
- Biased Agonism & Allosteric Modulation: To overcome tachyphylaxis and prolactin elevation, biased GHSR agonists (e.g., β-arrestin bias) are being explored.
The future outlook emphasizes precision biomarker stratification (acyl vs. des-acyl ghrelin ratio), dual-pathway targeting (e.g., GHRL + GLP1R), and muscle-preserving metabolic therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| GHSR Small Molecule Agonist | Helsinn (Anamorelin), Ono, Aeterna Zentaris (Macimorelin) | Cancer Cachexia, Adult GH Deficiency (diagnosis) | Receptor binding & cAMP accumulation (need GHSR lentivirus cell lines); selectivity over other GPCRs. |
| Ghrelin Peptide Mimetic / Analog | AbbVie (Relamorelin), Academic groups | Cachexia, GI Motility, Anorexia | Serum stability & DPP-IV resistance (need modified GHRL mutant proteins); receptor activation assay. |
| Anti-GHRL Monoclonal Antibody | Novo Nordisk, Lilly (research phase) | Obesity, Prader-Willi Syndrome | High-affinity binding assay (need purified GHRL antigen); neutralization validation (need GHSR cell line). |
| Vaccine / Immunotherapy | Legacy Novartis (discontinued), Academic | Obesity | Immunogenicity testing (need GHRL-carrier conjugates); epitope mapping (need full-length protein). |
| GOAT (MBOAT4) Inhibitor | Research institutions | Metabolic Syndrome | Enzyme activity assay (need acyl-ghrelin detection standards); GOAT protein/lysate. |